Aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's initial focus is on advancing AV-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonar...See more
Headquarter United States of America |
Countries of operation United States of America, Australia |
Funding status Private |
Company type SME |